This method provides a gene profiling of oncogene-addicted NSCLC patients who progressed to first-line target treatment, thus identifying acquired ALK resistance mutations and other gene alterations responsible for therapy failure [82,83]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.